Possible Causes of imAEs

Slides:

Advertisements

Similar presentations

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Advertisements

1 LYMErix  Lyme Disease Vaccine (Recombinant Osp A) Center for Biologics Evaluation and Research May 21, 2002.

Principles of Clinical Pathology Why do we Need to Study General Medical Issues?

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Upfront Combination Therapy vs Step-Up Approach for PAH:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

HIV-Associated Weight Loss and Wasting

Team 1: 32 responses Team 2: 55 responses Team 3: 29 responses

Tips Need to Consider When Organizing a College Event

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Does One Size Fit All in Obesity Management?

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

The Tumor Microenvironment

The ABCs of Nitric Oxide in the Skin

Case Challenges in Chronic Migraine

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

The Art and Science of Diagnosing Seizures

Chronic Idiopathic Urticaria

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

ماجستير إدارة المعارض من بريطانيا

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Translating Atopic Dermatitis

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Statins and Glucose Metabolism: Are All Agents Alike?

Checkpoint Inhibition

Multidisciplinary Perspectives on Interstitial Lung Diseases

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

A Journal Club on Lipid Management:

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Skin.

Managing Adverse Events With New Oral Therapies in CLL

Charting Progress in MS Treatment:

Immunotherapy for cSCC

HIV Treatment: What Can You Do to Get and Keep Patients in Care?

Hiding in Plain Sight: How Cancer Evades the Immune System

Managing Polycythemia Vera in the Community Setting

Improving Outcomes in Psoriatic Arthritis

Management of Systemic Lupus Erythematosus

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient Questions and Expert Answers in Psoriasis:

Insulin in Diabetes Management: Effective Patient Selection Is Key

Incorporating Prostacyclins Into Practice

Nurse Practitioners: At the Forefront of HPV-Related Disease Prevention.

Strengthening Lung Cancer Team Connections to Improve Outcomes With Immunotherapy.

Program Goal. Program Goal Disclaimer Overview.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Educational Objectives

Getting PPG Under Control

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

AMD Therapy: Where Are We Now and Where Are We Going?

MS, Age, and Immune Function

Pulmonary Arterial Hypertension and Hospitalizations

The Building Blocks of Homocystinuria and Homocysteinemia Management

Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Exploring the Use of Adeno-Associated Virus for Gene Therapy

The Nurse View.

Expert Perspectives.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Best Practices in Building HIV Care Networks

Presentation transcript:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the CNS

Possible Causes of imAEs

Onset of imAEs

General Management of imAEs

Neurologic imAEs

Experience With Neurologic imAEs

Variety of Neurologic imAEs

General Principles of Management of Neurologic imAEs

Diagnostic Workup

General Principles of Management of Neurologic imAEs

Multidisciplinary Team

Case 1

Case Discussion

Hypophysitis

Case 2

Case Discussion

Case (cont)

Myasthenia Gravis

Case 3

Case Discussion

Limbic Encephalopathy

Case 4

Case Discussion

Transverse Myeloradiculitis

Concluding Remarks

Abbreviations

Abbreviations (cont)